Abstract:Background: One of the key risk factors for cardiovascular disease is hypertension. Hypertension, which leads to heart attacks and strokes, already affects one billion people worldwide, making it a global public health issue. Incidence and prevalence of the condition is on the rise in low- and middle-income countries, with the biggest increase in sub-Saharan Africa and South Africa at the forefront. We examined the prevalence, incidence, predictors, treatment, and control of hypertension among HIV-positive patients on ART in a large South African observational cohort. Methods: We conducted a prospective study of ART naïve adults initiating ART at a public sector HIV clinic in South Africa between April 2004-2017. Patients with diagnosed hypertension at ART initiation were excluded from the incidence analysis. Log-binomial regression was used to estimate predictors of hypertension at ART initiation, while competing risks regression was used to evaluate the relationship between predictors of incident hypertension, accounting for death as a competing risk. Results: Among 77,696 eligible patients, 22.0% had prevalent hypertension at ART initiation. Of the remaining patients with no hypertension at ART initiation, 8,125 incident hypertension cases were diagnosed over the period of follow-up, corresponding to an incident rate of 5.4 per 100 person-years (95% confidence interval (CI): 5.3-5.6). We found patients ≥40 years of age and patients with a body mass index (BMI) ≥25kg/m2 were at increased risk of both prevalent and incident hypertension. Male patients and those with pre-hypertension at ART initiation had increased hazards of hypertension over the period of follow-up. When assessing the choice of antiretroviral drug in first-line ART, patients initiated on nevirapine were at 27% increased risk of developing hypertension compared to those initiated on efavirenz, while patients who initiated on either zidovudine or stavudine had a 40% increased risk of developing hypertension compared to patients initiated on tenofovir. Patientswith poorer health status at ART initiation (i.e. WHO III/IV stage, low CD4 count, low hemoglobin levels and low BMI) had a decrease risk of prevalent hypertension. We found an inverse relationship in patients with a CD4 count <50 cells/mm3 at ART initiation who had a 25% increased risk of incident hypertension compared to those with a CD4 count ≥350 cells/mm3. Conclusion: Over 20% of patients in our cohort had hypertension at ART initiation, and 13% of those with normal blood pressure at ART initiation developed hypertension while on ART. Older patients, males, those on nevirapine, zidovudine or stavudine, and those who are overweight/obese should be targeted for frequent blood pressure monitoring and the identification of other cardiovascular risk factors to encourage lifestyle modifications. Additionally, these groups should be offered pharmaceutical therapy to help prevent myocardial infarction, heart failure, stroke, and kidney disease. Further research is needed to determine the level of access and adherence to pharmaceutical treatment for hypertension in this population. Additionally, an HIV-negative comparison population is needed to assess the association of the HIV virus itself with hypertension.

General and Abdominal Obesity and Incident Hypertension among People Living with HIV on Antiretroviral Therapy.

Differences in Hypertension and Prehypertension among People Living with and Without HIV in China: Role of HIV Infection and Antiretroviral Therapy

Increasing Trends of Overweight and Obesity in Treatment-Naive People Living with HIV in Shenzhen from 2014 to 2020: an Emerging Health Concern

Hypertension Prevalence and Control Among People With and Without HIV — United States, 2022

Cardiometabolic Characteristics of Obesity Phenotypes in Persons With HIV

Hypertension and antihypertensive treatment in HIV-infected individuals. A longitudinal cohort study

Incidence and prevalence of hypertension among HIV-TB co-infected participants accessing treatment: A five-year prospective cohort analysis

Prevalence, incidence, predictors, treatment, and control of hypertension among HIV-positive adults on antiretroviral treatment in public sector treatment programs in South Africa

Inflammation markers and the risk of hypertension in people living with HIV

Prevalence, Awareness, and Factors Associated with Hypertension Among People Living with HIV in Eastern Uganda. A Multicentre Cross-Sectional Study

Obesity Defining Criteria, and Association with Cardiovascular Disease Risk Factors Among People Living with HIV in Jos, Nigeria

Hypertension in HIV-Infected Adults Compared with Similar but Uninfected Adults in China: Body Mass Index-Dependent Effects of Nadir CD4 Count.

Changes in Body Mass Index Over Time in People With and Without HIV Infection

Hypertension among people living with human immunodeficiency virus in sub-Saharan Africa: a systematic review and meta-analysis

Prevalence of Obesity, Abdominal Obesity and Associated Factors in Hypertensive Adults Aged 45-75 Years.

Prevalence of hypertension and diabetes and associated risk factors among people living with human immunodeficiency virus in Southern Ethiopia

Interaction between antiretroviral therapy regimens and body mass index on triglyceride levels in people living with HIV: a cross-sectional and longitudinal study

Weight Gain in Overweight and Obese People with HIV—The OBHIV Cohort

Higher cardiovascular disease risks in people living with HIV: A systematic review and meta-analysis

Longitudinal analysis of new-onset non-AIDS-defining diseases among people living with HIV: A real-world observational study

Time to incident hypertension and independent predictors among people living with HIV in Nigeria